Here are five key notes:
1. In exchange for the transfer of development and commercialization rights, Histogenics will pay a success-based milestone to Purpose upon conditional approval of NeoCart in Japan.
2. Histogenics will also pay commercial milestones and a low single-digit royalty on Japanese sales of NeoCart, upon full approval.
3. NeoCart is a Phase 3 investigational product that uses many aspects of Histogenics’ regenerative medicine platform to repair knee cartilage damage.
4. The Japanese market for cartilage repair is growing due to numerous factors, including new regulations. The Japanese Regenerative Medicine Law was passed in 2014 to potentially expedite the clinical development and commercialization pathways for regenerative cell-based medicines.
5. Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment.
More articles on devices:
Blue Belt Technologies co-founder wins outstanding entrepreneur award: 5 things to know
Novastep, Vivex Biomedical partner: 4 points
45 spine, orthopedic devices receive FDA 510(k) clearance in April
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
